Rivaroxaban

Identification

Summary

Rivaroxaban is a factor Xa inhibitor used to treat deep vein thrombosis (DVT) and pulmonary embolism (PE). May also be used as thrombosis prophylaxis in specific situations.

Brand Names
Xarelto
Generic Name
Rivaroxaban
DrugBank Accession Number
DB06228
Background

Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.

Type
Small Molecule
Groups
Approved
Structure
Weight
Average: 435.881
Monoisotopic: 435.065569098
Chemical Formula
C19H18ClN3O5S
Synonyms
  • Rivaroxaban
External IDs
  • BAY 59-7939
  • BAY-59-7939
  • JNJ-39039039
  • JNJ39039039

Pharmacology

Indication

Rivaroxaban is indicated for the prevention of venous thromboembolic events (VTE) in patients who have undergone total hips replacements and total knee replacement surgery; prevention of stroke and systemic embolism in patients with nonvalvular atrial fibrillation; treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE); to reduce risk of recurrent DVT and/or PE. Rivaroxaban is also indicated, in combination with aspirin, for reducing the risk of major cardiovascular events in patients with chronic coronary artery disease or peripheral artery disease. Its use is also not recommended in those with severe renal impairment (<30mL/min).7

Rivaroxaban is also indicated for the treatment and prevention of VTE in pediatric patients (from birth to 18 years of age) and for thromboprophylaxis in pediatric patients ≥2 years old with congenital heart disease following the Fontan procedure.7

Reduce drug development failure rates
Build, train, & validate machine-learning models
with evidence-based and structured datasets.
See how
Build, train, & validate predictive machine-learning models with structured datasets.
See how
Associated Conditions
Indication TypeIndicationCombined Product DetailsApproval LevelAge GroupPatient CharacteristicsDose Form
Used in combination to preventCardiovascular deathRegimen in combination with: Acetylsalicylic acid (DB00945)••••••••••••••••••• •••• ••••••
Prophylaxis ofDeep vein thrombosis••••••••••••••••••• •••• ••••••
Treatment ofDeep vein thrombosis••••••••••••••••••• •••• ••••••
Prophylaxis ofDeep vein thrombosis••••••••••••••••••• •••• ••••••
Prevention ofMajor adverse cardiovascular events•••••••••••••••••••• •••••• ••••••• •••••••••••
Contraindications & Blackbox Warnings
Prevent Adverse Drug Events Today
Tap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.
Learn more
Avoid life-threatening adverse drug events with our Clinical API
Learn more
Pharmacodynamics

Rivaroxaban is an anticoagulant which binds directly to factor Xa. Thereafter, it effectively blocks the amplification of the coagulation cascade, preventing the formation of thrombus. Rivaroxaban is a unqiue anticoagulant for two reasons. First of all, it is does not involve antithrombin III (ATIII) to exert its anticoagulant effects. Secondly, it is an oral agent whereas the widely used unfractionated heparin and low molecular weight heparins are for parenteral use only. Although the activated partial thromboplastin time (aPTT) and HepTest (a test developed to assay low molecular weight heparins) are prolonged in a dose-dependant manner, neither test is recommended for the assessment of the pharmacodynamic effects of rivaroxaban. Anti-Xa activity and inhibition of anti-Xa activity monitoring is also not recommended despite being influenced by rivaroxaban.

Mechanism of action

Rivaroxaban competitively inhibits free and clot bound factor Xa. Factor Xa is needed to activate prothrombin (factor II) to thrombin (factor IIa). Thrombin is a serine protease that is required to activate fibrinogen to fibrin, which is the loose meshwork that completes the clotting process. Since one molecule of factor Xa can generate more than 1000 molecules of thrombin, selective inhibitors of factor Xa are profoundly useful in terminating the amplification of thrombin generation. The action of rivaroxaban is irreversible.

TargetActionsOrganism
ACoagulation factor X
antagonist
Humans
Absorption

Following oral administration, rivaroxaban is rapidly absorbed and reaches peak plasma concentration in 2-4 hours. Bioavailability of the 10 mg dose is >80%. However, the 15-20 mg dose have a lower bioavailability if taken in the fasted state and consequently should be taken with food.

Volume of distribution

The steady state Vd is 50 L

Protein binding

Plasma protein binding is about 92% to 95%

Metabolism

Approximately two-thirds of the dose is metabolized. It is metabolized by CYP3A4, CYP3A5, CYP2J2 and CYP-independant mechanisms

Route of elimination

Approximately two-thirds of rivaroxaban is excreted into urine (via active tubular secretion in which approximately 36% as unchanged drug and 30% as inactive metabolism). The remaining third of the administered dose is excreted via feces in which 7% is in the form of unchanged drug and 21% as inactive metabolites.

Half-life

The terminal half life is 5-9 hours in adults and 11-13 hours in the elderly.

Clearance

Systemic clearance is approximately 10 L/h, so rivaroxaban is considered a drug with low clearance. Renal clearance is ~3-4 L/h.

Adverse Effects
Improve decision support & research outcomes
With structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!
See the data
Improve decision support & research outcomes with our structured adverse effects data.
See a data sample
Toxicity

Excessive bleeding. Overdosages should be treated using activated charcoal and supportive measures such as mechanical compression and hemodynamic support. If bleeding is not controlled, the following procoagulants can be administered: activated prothrombin complex concentrate, prothrombin complex concentrate and recombinant factor VIIa. There is also a higher chance of post procedural hemorrhage compared to enoxaparin (1.55% vs. 1.39% respectively).

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AbacavirAbacavir may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
AbametapirThe serum concentration of Rivaroxaban can be increased when it is combined with Abametapir.
AbataceptThe metabolism of Rivaroxaban can be increased when combined with Abatacept.
AbciximabAbciximab may increase the anticoagulant activities of Rivaroxaban.
AbemaciclibAbemaciclib may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.
Food Interactions
  • Avoid herbs and supplements with anticoagulant/antiplatelet activity. Examples include garlic, ginger, bilberry, danshen, piracetam, and ginkgo biloba.
  • Avoid St. John's Wort. Co-administration will decrease levels of this medication.
  • Take with food. Rivaroxaban 15-20mg dose should be taken with food as food significantly impacts the bioavailability at that dose.
  • Take with or without food. Rivaroxaban 10mg dose can be taken with or without food as it does not significantly impact the bioavailability at that dose.

Products

Drug product information from 10+ global regions
Our datasets provide approved product information including:
dosage, form, labeller, route of administration, and marketing period.
Access now
Access drug product information from over 10 global regions.
Access now
Product Images
Brand Name Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Nra-rivaroxabanTablet20 mgOralNora Pharma IncNot applicableNot applicableCanada flag
Nra-rivaroxabanTablet2.5 mgOralNora Pharma IncNot applicableNot applicableCanada flag
Nra-rivaroxabanTablet15 mgOralNora Pharma IncNot applicableNot applicableCanada flag
Nra-rivaroxabanTablet10 mgOralNora Pharma IncNot applicableNot applicableCanada flag
Pmsc-rivaroxabanTablet15 mgOralPharmascience IncNot applicableNot applicableCanada flag
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing EndRegionImage
Ach-rivaroxabanTablet20 mgOralAccord Healthcare IncNot applicableNot applicableCanada flag
Ach-rivaroxabanTablet15 mgOralAccord Healthcare IncNot applicableNot applicableCanada flag
Ach-rivaroxabanTablet2.5 mgOralAccord Healthcare IncNot applicableNot applicableCanada flag
Ach-rivaroxabanTablet10 mgOralAccord Healthcare IncNot applicableNot applicableCanada flag
Apo-rivaroxabanTablet10 mgOralApotex Corporation2023-11-01Not applicableCanada flag
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing EndRegionImage
XareltoRivaroxaban (15 mg) + Rivaroxaban (20 mg)Kit; TabletOralBayer2015-11-022018-12-01Canada flag
XareltoRivaroxaban (15 mg/1) + Rivaroxaban (20 mg/1)Kit; Tablet, film coatedOralJanssen Pharmaceuticals, Inc.2014-09-16Not applicableUS flag
XARELTORivaroxaban (15 MG) + Rivaroxaban (20 MG)Tablet, film coatedOralBayer Ag2018-09-04Not applicableItaly flag
XareltoRivaroxaban (15 mg) + Rivaroxaban (20 mg)Kit; TabletOralBayer2015-11-022018-12-01Canada flag
XARELTORivaroxaban (15 MG) + Rivaroxaban (20 MG)Tablet, film coatedOralBayer Ag2018-09-04Not applicableItaly flag

Categories

ATC Codes
B01AF01 — Rivaroxaban
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as phenylmorpholines. These are aromatic compounds containing a morpholine ring and a benzene ring linked to each other through a CC or a CN bond.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Oxazinanes
Sub Class
Morpholines
Direct Parent
Phenylmorpholines
Alternative Parents
Thiophene carboxamides / 2-heteroaryl carboxamides / 2,5-disubstituted thiophenes / Oxazolidinones / Aryl chlorides / Benzene and substituted derivatives / Tertiary carboxylic acid amides / Carbamate esters / Heteroaromatic compounds / Secondary carboxylic acid amides
show 11 more
Substituents
2,5-disubstituted thiophene / 2-heteroaryl carboxamide / Aromatic heteromonocyclic compound / Aryl chloride / Aryl halide / Azacycle / Benzenoid / Carbamic acid ester / Carbonic acid derivative / Carbonyl group
show 25 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
monocarboxylic acid amide, organochlorine compound, thiophenes, lactam, aromatic amide, morpholines, oxazolidinone (CHEBI:68579)
Affected organisms
  • Humans and other mammals

Chemical Identifiers

UNII
9NDF7JZ4M3
CAS number
366789-02-8
InChI Key
KGFYHTZWPPHNLQ-AWEZNQCLSA-N
InChI
InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
IUPAC Name
5-chloro-N-{[(5S)-2-oxo-3-[4-(3-oxomorpholin-4-yl)phenyl]-1,3-oxazolidin-5-yl]methyl}thiophene-2-carboxamide
SMILES
ClC1=CC=C(S1)C(=O)NC[C@H]1CN(C(=O)O1)C1=CC=C(C=C1)N1CCOCC1=O

References

Synthesis Reference

Prabhudas BODHURI, Gamini Weeratunga, "PROCESSES FOR THE PREPARATION OF RIVAROXABAN AND INTERMEDIATES THEREOF." U.S. Patent US20100273790, issued October 28, 2010.

US20100273790
General References
  1. Piccini JP, Patel MR, Mahaffey KW, Fox KA, Califf RM: Rivaroxaban, an oral direct factor Xa inhibitor. Expert Opin Investig Drugs. 2008 Jun;17(6):925-37. doi: 10.1517/13543784.17.6.925 . [Article]
  2. Alban S: Pharmacological strategies for inhibition of thrombin activity. Curr Pharm Des. 2008;14(12):1152-75. [Article]
  3. Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E: Rivaroxaban for the prevention of venous thromboembolism: a single technology appraisal. Health Technol Assess. 2009 Oct;13 Suppl 3:43-8. doi: 10.3310/hta13suppl3/07. [Article]
  4. Imberti D, Dall'Asta C, Pierfranceschi MG: Oral factor Xa inhibitors for thromboprophylaxis in major orthopedic surgery: a review. Intern Emerg Med. 2009 Dec;4(6):471-7. doi: 10.1007/s11739-009-0293-9. [Article]
  5. Alexander D, Jeremias A: Rivaroxaban in the contemporary treatment of acute coronary syndromes. Expert Opin Investig Drugs. 2011 Jun;20(6):849-57. doi: 10.1517/13543784.2011.580274. Epub 2011 May 10. [Article]
  6. Cabral KP: Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40. doi: 10.1007/s11239-013-0929-5. [Article]
  7. FDA Approved Products: XARELTO (rivaroxaban) tablets or suspension, for oral use [Link]
  8. FDA Approved Drug Products: Xarelto (rivaroxaban) tablets/suspension for oral administration (February 2023) [Link]
KEGG Drug
D07086
PubChem Compound
9875401
PubChem Substance
175427064
ChemSpider
8051086
BindingDB
7840
RxNav
1114195
ChEBI
68579
ChEMBL
CHEMBL198362
ZINC
ZINC000003964126
PDBe Ligand
RIV
RxList
RxList Drug Page
Drugs.com
Drugs.com Drug Page
Wikipedia
Rivaroxaban
PDB Entries
2w26 / 5vof
MSDS
Download (480 KB)

Clinical Trials

Clinical Trials

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
TabletOral15.000 mg
TabletOral10.000 mg
Tablet, coatedOral15 mg
TabletOral2.500 mg
Tablet, film coatedOral15 MG
Tablet, film coatedOral20 MG
Tablet, film coatedOral15 mg/20mg
Tablet, film coatedOral
CapsuleOral15 mg
CapsuleOral20 mg
CapsuleOral10 MG
CapsuleOral2.5 MG
TabletOral10.0000 mg
GranuleOral1 MG/ML
Granule, for suspensionOral103.4 mg / bottle
Granule, for suspensionOral155 mg/1
Granule, for suspensionOral51.7 mg / bottle
Kit; tabletOral
Kit; tablet, film coatedOral
SuspensionOral103.40 mg
TabletOral10 mg
TabletOral10.00 mg
TabletOral15 mg
TabletOral2.5 mg
TabletOral20 mg
Tablet, film coatedOral
Tablet, film coatedOral10 mg/1
Tablet, film coatedOral15 mg/1
Tablet, film coatedOral2.5 mg/1
Tablet, film coatedOral20 mg/1
Tablet, film coatedOral10 mg
Tablet, film coatedOral15.00 mg
Tablet, film coatedOral20.00 mg
Tablet, coatedOral
TabletOral20.000 mg
Tablet, coatedOral2.5 mg
Tablet, film coatedOral2.5 mg
Tablet, coatedOral10 mg
Tablet, coatedOral20 mg
Prices
Not Available
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)Region
CA2396561No2008-10-142020-12-11Canada flag
CA2547113No2012-01-242024-11-13Canada flag
US7157456Yes2007-01-022025-02-28US flag
US7585860No2009-09-082020-12-11US flag
US7592339No2009-09-222020-12-11US flag
US9539218Yes2017-01-102034-08-17US flag
US9415053Yes2016-08-162025-05-13US flag
US10828310Yes2020-11-102039-07-31US flag

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.01 mg/mLALOGPS
logP1.74ALOGPS
logP1.9Chemaxon
logS-4.6ALOGPS
pKa (Strongest Acidic)13.6Chemaxon
pKa (Strongest Basic)-1.6Chemaxon
Physiological Charge0Chemaxon
Hydrogen Acceptor Count5Chemaxon
Hydrogen Donor Count1Chemaxon
Polar Surface Area88.18 Å2Chemaxon
Rotatable Bond Count5Chemaxon
Refractivity104.74 m3·mol-1Chemaxon
Polarizability43.39 Å3Chemaxon
Number of Rings4Chemaxon
Bioavailability1Chemaxon
Rule of FiveYesChemaxon
Ghose FilterYesChemaxon
Veber's RuleNoChemaxon
MDDR-like RuleNoChemaxon
Predicted ADMET Features
PropertyValueProbability
Human Intestinal Absorption+0.9966
Blood Brain Barrier+0.9462
Caco-2 permeable+0.6822
P-glycoprotein substrateNon-substrate0.5691
P-glycoprotein inhibitor IInhibitor0.6325
P-glycoprotein inhibitor IIInhibitor0.5601
Renal organic cation transporterNon-inhibitor0.7562
CYP450 2C9 substrateNon-substrate0.7866
CYP450 2D6 substrateNon-substrate0.8761
CYP450 3A4 substrateSubstrate0.5964
CYP450 1A2 substrateNon-inhibitor0.6469
CYP450 2C9 inhibitorNon-inhibitor0.7035
CYP450 2D6 inhibitorNon-inhibitor0.7516
CYP450 2C19 inhibitorInhibitor0.6475
CYP450 3A4 inhibitorNon-inhibitor0.6667
CYP450 inhibitory promiscuityHigh CYP Inhibitory Promiscuity0.7463
Ames testNon AMES toxic0.6162
CarcinogenicityNon-carcinogens0.8838
BiodegradationNot ready biodegradable0.9844
Rat acute toxicity2.4353 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8938
hERG inhibition (predictor II)Inhibitor0.6205
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSsplash10-000i-0000900000-e6e423d4ca7f5ebe5767
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSsplash10-052f-1934300000-ba2cc97a89aca3b5799e
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSsplash10-002r-0032900000-f5c321968bcf6c28d9fd
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSsplash10-00mo-0194100000-912ba9638c151892a3a2
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSsplash10-0kfx-2138900000-6669bf414df224cf238f
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSsplash10-047l-3189200000-766cf9fb0d8b855bc057
Predicted 1H NMR Spectrum1D NMRNot Applicable
Predicted 13C NMR Spectrum1D NMRNot Applicable
Chromatographic Properties
Collision Cross Sections (CCS)
AdductCCS Value (Å2)Source typeSource
[M-H]-193.4684
predicted
DeepCCS 1.0 (2019)
[M+H]+195.8264
predicted
DeepCCS 1.0 (2019)
[M+Na]+202.34598
predicted
DeepCCS 1.0 (2019)

Targets

Build, predict & validate machine-learning models
Use our structured and evidence-based datasets to unlock new
insights and accelerate drug research.
Learn more
Use our structured and evidence-based datasets to unlock new insights and accelerate drug research.
Learn more
Details
1. Coagulation factor X
Kind
Protein
Organism
Humans
Pharmacological action
Yes
Actions
Antagonist
General Function
Serine-type endopeptidase activity
Specific Function
Factor Xa is a vitamin K-dependent glycoprotein that converts prothrombin to thrombin in the presence of factor Va, calcium and phospholipid during blood clotting.
Gene Name
F10
Uniprot ID
P00742
Uniprot Name
Coagulation factor X
Molecular Weight
54731.255 Da
References
  1. Melillo SN, Scanlon JV, Exter BP, Steinberg M, Jarvis CI: Rivaroxaban for thromboprophylaxis in patients undergoing major orthopedic surgery. Ann Pharmacother. 2010 Jun;44(6):1061-71. doi: 10.1345/aph.1M681. Epub 2010 Apr 27. [Article]
  2. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [Article]
  3. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE: The Protein Data Bank. Nucleic Acids Res. 2000 Jan 1;28(1):235-42. [Article]

Enzymes

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
This enzyme metabolizes arachidonic acid predominantly via a NADPH-dependent olefin epoxidation to all four regioisomeric cis-epoxyeicosatrienoic acids. One of the predominant enzymes responsible f...
Gene Name
CYP2J2
Uniprot ID
P51589
Uniprot Name
Cytochrome P450 2J2
Molecular Weight
57610.165 Da
References
  1. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Oxygen binding
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP3A5
Uniprot ID
P20815
Uniprot Name
Cytochrome P450 3A5
Molecular Weight
57108.065 Da
References
  1. Cabral KP: Pharmacology of the new target-specific oral anticoagulants. J Thromb Thrombolysis. 2013 Aug;36(2):133-40. doi: 10.1007/s11239-013-0929-5. [Article]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Mismetti P, Laporte S: [Rivaroxaban: clinical pharmacology]. Ann Fr Anesth Reanim. 2008 Dec;27 Suppl 3:S16-21. doi: 10.1016/S0750-7658(08)75142-6. [Article]
  2. Ufer M: Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost. 2010 Mar;103(3):572-85. doi: 10.1160/TH09-09-0659. Epub 2010 Feb 2. [Article]

Transporters

Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name
ABCB1
Uniprot ID
P08183
Uniprot Name
Multidrug resistance protein 1
Molecular Weight
141477.255 Da
References
  1. Walenga JM, Adiguzel C: Drug and dietary interactions of the new and emerging oral anticoagulants. Int J Clin Pract. 2010 Jun;64(7):956-67. doi: 10.1111/j.1742-1241.2009.02286.x. [Article]
  2. Chen T, Lam S: Rivaroxaban: an oral direct factor Xa inhibitor for the prevention of thromboembolism. Cardiol Rev. 2009 Jul-Aug;17(4):192-7. doi: 10.1097/CRD.0b013e3181aa2154. [Article]
  3. FDA Approved Products: XARELTO (rivaroxaban) tablets or suspension, for oral use [Link]
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
Actions
Substrate
General Function
Xenobiotic-transporting atpase activity
Specific Function
High-capacity urate exporter functioning in both renal and extrarenal urate excretion. Plays a role in porphyrin homeostasis as it is able to mediates the export of protoporhyrin IX (PPIX) both fro...
Gene Name
ABCG2
Uniprot ID
Q9UNQ0
Uniprot Name
ATP-binding cassette sub-family G member 2
Molecular Weight
72313.47 Da
References
  1. Mueck W, Kubitza D, Becka M: Co-administration of rivaroxaban with drugs that share its elimination pathways: pharmacokinetic effects in healthy subjects. Br J Clin Pharmacol. 2013 Sep;76(3):455-66. doi: 10.1111/bcp.12075. [Article]
  2. Xarelto FDA [File]

Drug created at March 19, 2008 16:18 / Updated at March 03, 2024 18:31